Efficacy and Safety of Switching from Sitagliptin to Ipragliflozin in Obese Japanese Patients with Type 2 Diabetes Mellitus: A Single-Arm Multicenter Interventional Study-Reference-Cited by-同舟云学术

Efficacy and Safety of Switching from Sitagliptin to Ipragliflozin in Obese Japanese Patients with Type 2 Diabetes Mellitus: A Single-Arm Multicenter Interventional Study

Published:2023-11-07 Issue:12 Volume:43 Page:927-937
ISSN:1173-2563
Container-title:Clinical Drug Investigation
language:en
Short-container-title:Clin Drug Investig

Author:

Watanabe Kentaro^ORCID,Yamaguchi Susumu,Kosakai Yoshinori,Ioji Tetsuya,Ishihara Hisamitsu

Funder

Astellas Pharma

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s40261-023-01317-z.pdf

Reference43 articles.

1. Marín-Peñalver JJ, Martín-Timón I, Sevillano-Collantes C, del Cañizo-Gómez FJ. Update on the treatment of type 2 diabetes mellitus. World J Diabetes. 2016;7:354–5. https://doi.org/10.4239/wjd.v7.i17.354.

2. ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, on behalf of the American Diabetes Association, et al. Pharmacological approaches to glycemic treatment: standards of Medical Care in Diabetes-2023. Diabetes Care. 2023;46(Suppl. 1):S140–57. https://doi.org/10.2337/dc23-S009.

3. Bouchi R, Sugiyama T, Goto A, Imai K, Ihara-Sugiyama N, Ohsugi M, et al. Retrospective nationwide study on the trends in first-line antidiabetic medication for patients with type 2 diabetes in Japan. J Diabetes Investig. 2022;13:280–91. https://doi.org/10.4093/dmj.2011.35.3.300.

4. Kim SA, Shim WH, Lee EH, Lee YM, Beom SH, Kim ES, et al. Predictive clinical parameters for the therapeutic efficacy of sitagliptin in Korean type 2 diabetes mellitus. Diabetes Metab J. 2011;35:159–65. https://doi.org/10.4093/dmj.2011.35.3.300.

5. Sakai S, Kaku K, Seino Y, Inagaki N, Haneda M, Sasaki T, et al. Efficacy and safety of the SGLT2 inhibitor luseogliflozin in Japanese patients with type 2 diabetes mellitus stratified according to baseline body mass index: pooled analysis of data from 52-week phase III trials. Clin Ther. 2016;38:843–62. https://doi.org/10.1016/j.clinthera.2016.01.017.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapy Combining Glucagon-Like Peptide-1 Receptor Agonist with Sodium-Glucose Cotransporter 2 Inhibitor Suppresses Atherosclerosis in Diabetic ApoE-Deficient Mice;Experimental and Clinical Endocrinology & Diabetes;2024-04-16